A drug being developed by a Roivant subsidiary for a range of autoimmune conditions succeeded in a mid-stage trial in an eye disease that can ultimately lead to blindness, Roivant said Tuesday.
The drug, brepocitinib, is being steered by a company called Priovant Therapeutics, which was formed as part of a deal between Roivant and Pfizer in 2021.Â
The Phase 2 study tested different doses the oral drug in a disease called non-infectious uveitis, or NIU, which causes inflammation in the eye that can result in blindness. The primary endpoint of the trial, which was not placebo-controlled, was treatment failure at 24 weeks, with a lower treatment failure signifying a greater treatment benefit. The study included 26 participants.
Click this link for the original source of this article.
Author: Andrew Joseph
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.